Theralase to Present Groundbreaking Research at ASTRO 2025
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is proud to announce promising new preclinical results. The Company's latest research demonstrates that radiation-activated Rutherrin® is up to 100 times more effective at destroying cancer cells than radiation therapy alone in comparable models.
This data will be showcased at the 2025 American Society for Radiation Oncology ('ASTRO') 67 th Annual Meeting, the world's largest gathering of radiation oncology professionals, taking place in late September in San Francisco, California. ASTRO has selected the Theralase® abstract titled, " Rutherrin® Activated by Radiation Therapy Induces Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models ", for presentation in a scientific poster session.
The study highlights the potent anti-cancer effects of Rutherrin®—a ruthenium-based small molecule drug formulated with recombinant human transferrin for intravenous administration. Once activated by ionizing radiation through a process known as Radio Dynamic Therapy ('RDT'), Rutherrin® initiates a two-phase cancer-killing response: the generation of Reactive Oxygen Species ('ROS') for immediate cytotoxicity, followed by Immunogenic Cell Death ('ICD') to stimulate a durable immune response.
Key Findings from the Preclinical Research:
Mark Roufaiel, Ph.D., research scientist at Theralase® commented, 'These results are highly encouraging. Rutherrin® not only enhances the effectiveness of radiation therapy, but also activates a sustained immune response, offering a powerful, dual-action strategy against aggressive and treatment-resistant cancers.'
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase®, added, 'Our focus is to bring this innovative platform to clinical application. Rutherrin® represents a major advancement in oncologic treatment, potentially enabling radiation oncologists to dramatically improve patient outcomes. This research provides a strong foundation for integrating Rutherrin® with existing cancer therapies to deliver more effective, long-lasting solutions.'
Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase®, stated, 'Based on this compelling data, we are fully committed to completing GLP toxicology studies in 2025. This critical milestone will support the launch of clinical studies in early 2026 targeting GBM, lung, pancreatic, lymphoma and colorectal cancers. We're excited to continue advancing Rutherrin® toward commercialization and transforming cancer care.'
About ASTRO
Founded in 1958, ASTRO's mission is to advance the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research, disseminating research results and representing radiation oncology in a rapidly evolving health care environment.
The ASTRO Annual Meeting is the premier event in radiation oncology, bringing together leading scientists, clinicians and industry partners to share groundbreaking research and technological innovations. The 2025 meeting in San Francisco will showcase cutting-edge advances in radiation biology, translational medicine and cancer therapeutics.
About Rutherrin®
Rutherrin® is a patented formulation of Theralase®'s lead ruthenium-based small molecule (Ruvidar®) combined with recombinant human transferrin making it suitable for intravenous delivery. It has the ability to selectively accumulate in cancer cells versus healthy cells and when radiation-activated provide a one-two punch to cancer, by first destroying the cancer cell through oxidative stress and then activating the immune system for destruction of residual cancer cells. Rutherrin® is slated to enter clinical studies in early 2026 for the destruction of deadly cancers; including: brain, lung, pancreatic, colorectal and lymphoma.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach outInvestor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253568
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Carbeeza Inc. Announces CEO Appointment
CALGARY, AB / / July 25, 2025 / Carbeeza Inc. ("Carbeeza" or the "Company") (TSXV:AUTO)(OTCQB:CRBAF) is pleased to announce the appointment of Kenneth W. Brizel as Chief Executive Officer of the Company, effective immediately. Mr. Brizel brings a wealth of executive leadership and capital markets experience to Carbeeza, with a demonstrated track record in scaling technology businesses and leading go-to-market strategies across emerging fintech sectors. As CEO, Mr. Brizel will lead Carbeeza's operational strategy, business development, investor relations, and regulatory compliance. Mr. Brizel has held senior executive positions with both public and private corporations, consistently driving the successful commercialization of advanced technology products. His extensive background includes leadership roles at prominent companies such as RCA/GE, Lucent Technologies, Oplink Communications, LightPath Technologies, ACAMP, ColdChase, Mostek, and Star Semiconductor. Over the course of his career, Mr. Brizel's responsibilities have spanned strategy and business development, engineering, manufacturing, sales, and marketing-making him uniquely qualified to lead Carbeeza in a rapidly evolving market landscape. "I am honored to join Carbeeza at such a pivotal time," said Mr. Brizel. "The company has a strong foundation, a talented team, and a compelling vision. I look forward to working closely with our stakeholders to accelerate growth, drive innovation, and create long-term value." Leadership Transition In conjunction with the CEO appointment, Carbeeza announces that Kenneth W. Brizel replaces Mark Tommasi, the current interim CEO. The Board of Directors extends its sincere thanks to Mark Tommasi for his dedicated efforts and valuable contributions in advancing the Company's objectives. Additionally, Carbeeza is pleased to announce that Joanna Hampton has agreed to rejoin the Company in her role as Chief Financial Officer (CFO). Her return brings valuable continuity and financial leadership to the executive team as the Company enters its next phase of growth. Equity Incentive Agreement In connection with his appointment, the Company has entered into an employment agreement with Mr. Brizel that includes an equity incentive component of up to 25,000,000 common shares of the Company (the "Shares"), issuable in tranches upon the achievement of defined performance-based milestones. These milestones include, among other things: (i) commercialization of the Company's first and second products; (ii) achieving profitability for each of the first and second products; and (iii) achieving consolidated net income of $0.05 per share (undiluted), prior to any share consolidation. The issuance of any Shares under the agreement is subject to: (i) TSX Venture Exchange ("TSXV") acceptance, (ii) disinterested shareholder approval, and (iii) compliance with TSXV Policy 4.4 - Security-Based Compensation. Once issued, such Shares will be subject to a four-month hold period under applicable Canadian securities laws. The Board of Directors believes this compensation structure aligns the long-term interests of management and shareholders, and appropriately incentivizes performance milestones that are expected to materially enhance shareholder value. About Carbeeza Inc. Carbeeza is a Canadian-based software company whose platform is targeted to the automotive marketplace. It is the first application to harness the power of Artificial Intelligence to accurately predict the best financing scenario for consumers, all while keeping the consumer anonymous. Using state-of-the-art technology, Carbeeza brings the process of buying a car right to the phone, tailor-made for the consumer. Carbeeza is highly beneficial to both consumers and auto dealers. ON BEHALF OF THE BOARD OF DIRECTORS OF CARBEEZA INC. Ken Brizel, Chairman Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. For further information please contact: Ken BrizelCEOCarbeeza Notice Regarding Forward-Looking Information: This news release contains forward-looking statements including but not limited to statements regarding the Company's business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above. SOURCE: Carbeeza Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNBC
2 hours ago
- CNBC
Southwest offers new 100,000-point bonus as it revamps its credit cards
Southwest Airline's seating policy isn't the only thing that's changing; the airline and Chase announced updates to the Southwest Rapid Rewards credit cards — adding enhanced benefits like pre-flight seat selection and early boarding, new earning categories and a welcome bonus any loyal Southwest flyer would love. For a limited time, now through Sep. 17, new Southwest Rapid Rewards Priority, Premier or Plus consumer credit cardmembers can earn 100,000 bonus points after spending $4,000 in the first five months from account opening. This is double the previous welcome bonus of 50,000 points, and it marks Southwest's best points offer this year. Along with the additional perks come other costs: card annual fees are increasing and Southwest will be expiring a few current benefits and reward categories. Here's a breakdown by card: Offers in this section are from affiliate partners and selected based on a combination of engagement, product relevance, compensation, and consistent Saint offers three packages for credit repair services and a 90-day money-back guarantee for services. It has received an A rating and is accredited by the Better Business Credit People's Credit Report Repair service is relatively affordable compared to other programs in the space. Even the most basic package (the standard package) includes unlimited challenges to all three credit bureaus. Upgrading to the premium package includes escalated disputes and monthly credit score reports and score refreshes. On Chase's site On Chase's site Good to Excellent670–850 19.99% - 28.49% variable $99 Earn 100,000 points. See rates and fees. Terms apply. Member FDIC. Read our Southwest Rapid Rewards® Plus Credit Card review. The Southwest Rapid Rewards® Plus Credit Card is an affordable card that makes sense for the occasional Southwest $5 or 5% of the amount of each transfer, whichever is greater The Southwest Rapid Rewards Plus annual fee is rising from $69 to $99, a $30 hike. Good to Excellent670–850 20.49% - 27.49% variable $149 Earn 100,000 bonus points. Terms apply. Information about the Southwest Rapid Rewards® Premier Credit Card has been collected independently by Select and has not been reviewed or provided by the issuer of the card prior to publication. Read our Southwest Rapid Rewards Premier Credit Card review The Southwest Rapid Rewards® Premier Credit Card is Southwest's mid-tier card and is valuable if you regularly travel to or from destinations Southwest serves.5%, minimum $5 The Southwest Rapid Rewards Premier annual fee is increasing from $99 to $149, a $50 rise. On Chase's site On Chase's site Good to Excellent670–850 19.99% - 28.49% variable $229 Earn 100,000 points. See rates and fees. Terms apply. Member FDIC. Read our Southwest Rapid Rewards® Priority Credit Card review. The Southwest Rapid Rewards® Priority Credit Card is a perfect fit for serious Southwest fans who can easily maximize its benefits like upgraded boardings and an annual travel Southwest Rapid Rewards Priority annual fee is being hiked from $149 to $229, an $80 increase. Offers in this section are from affiliate partners and selected based on a combination of engagement, product relevance, compensation, and consistent availability. Good to Excellent670–850Earn 75,000 bonus points On Chase's site See rates and fees. Terms apply. Good to Excellent670–850Earn 75,000 miles Terms apply. The Southwest Rapid Rewards Plus Business is currently unavailable for new users, but carries a $99 annual fee. On Chase's site On Chase's site You can earn unlimited tier qualifying points for spending with this card. Good to Excellent670–850 19.99% - 28.49% variable $149 Earn 60,000 points See rates and fees. Terms apply. Member FDIC. Read our Southwest Rapid Rewards Premier Business Credit Card review The Southwest® Rapid Rewards® Premier Business Credit Card can help your business save on Southwest travel but offers less value for other $5 or 5% of the amount of each transfer, whichever is greater The Southwest Rapid Rewards Premier Business annual fee is increasing from $99 to $149, a $50 rise. On Chase's site On Chase's site Every account anniversary year you'll receive a 9,000-point bonus. Good to Excellent670–850 19.99% - 28.49% variable $299 Earn 80,000 points See rates and fees. Terms apply. Member FDIC. The Southwest® Rapid Rewards® Performance Business Credit Card is Southwest's most premium business credit card and can be incredibly rewarding for frequent flyers, especially those chasing the Southwest Companion Pass or other Southwest elite $5 or 5% of the amount of each transfer, whichever is greater The Southwest Rapid Rewards Performance Business annual fee is being bumped up from $199 to $299, a $100 increase. If you fly on Southwest with some frequency, chances are you'll be able to get some extra value out of these cards. Not only will you have opportunities when you book with Southwest, but with the addition of new rewards categories, you have more opportunities to earn Southwest Rapid Rewards, which can be redeemed for valuable rewards like flights and hotel stays. The Southwest cards are losing some benefits in categories like transit, internet and phone services, plus increasing annual fees. While a Southwest credit card may still make sense if you frequently travel with Southwest, it might be harder to earn rewards points if you don't often spend in the new rewards categories. Money matters — so make the most of it. Get expert tips, strategies, news and everything else you need to maximize your money, right to your inbox. Sign up here. At CNBC Select, our mission is to provide our readers with high-quality service journalism and comprehensive consumer advice so they can make informed decisions with their money. Every credit card article is based on rigorous reporting by our team of expert writers and editors with extensive knowledge of credit card products. While CNBC Select earns a commission from affiliate partners on many offers and links, we create all our content without input from our commercial team or any outside third parties, and we pride ourselves on our journalistic standards and ethics.


Business Upturn
5 hours ago
- Business Upturn
ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT
By GlobeNewswire Published on July 25, 2025, 21:22 IST Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — St. James Gold Corp. (the 'Company' or 'St. James') (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) announced today that its common shares will be reinstated for trading on the TSX Venture Exchange (the 'Exchange') on or about July 29, 2025 as the TSX Venture Exchange has completed its review. The Company's financial statements for the period ended March 31, 2025 reflected a working capital deficiency $1,905,769. In order to resolve the deficiency and comply with the Exchange listing requirements, the Company has taken the following steps: The Company has entered into agreements with its largest short-term creditors to issue unsecured notes with a maturity 18 month after issuance to satisfy their indebtedness. A total of $1,580,052.49 of short-term debt is expected to be resolved pending Exchange review and Exchange acceptance. The Company has written off $317,725 of indebtedness that was beyond the statutory limitation period. As a result of these transactions, and after closing of the Company's pending private placement, announced December 27, 2024, the adjusted working capital as at March 31, 2025, will be $129,209.49. Of the $1,580,052.49 a total of $1,222,758 represents management fees owed to current and former management. The agreements under which the fees were incurred were never filed or accepted by the Exchange. In addition, $917,068 of these fees exceeded the amounts permissible under Exchange policy. As a result the notes issued in satisfaction of those fees are non interest bearing and are subject to restriction on payment or conversion into stock without approval by a majority of the disinterested shareholders of the Company. The remaining notes that were issued in satisfaction of legal fees and disbursements and amounts advanced by a shareholder to pay Auditors bill bear interest at 10% per annum. The Company intends to seek approval of shares for debt to satisfy the unrestricted notes once the shares of the Company return to trading and the market has stabilized, and to seek approval of the shares for debt to satisfy the restricted notes once the required disinterested shareholder approval is obtained. About St James Gold Corp. St. James Gold Corp. is a publicly traded company listed on the TSX Venture Exchange under the trading symbol 'LORD', in the U.S. Market listed on OTCQB under 'LRDJF' and on the Frankfurt Stock Exchange under 'BVU3'. The Company is focused on creating shareholder value through the discovery and development of economic mineral deposits by acquiring prospective exploration projects with well-delineated geological theories; integrating all available geological, geochemical, and geophysical datasets; and financing efficient exploration programs. The Company currently holds: (i) 100-per-cent stake in 29 claims, covering 1,791 acres, in the Gander gold district in north-central Newfoundland located adjacent to New Found Gold Corp.'s Queensway North project; and (ii) a 100-per-cent stake in 9 claims and an option to acquire a further 100-per-cent interest in 19 claims, covering a total 1,730 acres, in central Newfoundland located adjacent to Marathon Gold's Valentine Lake property. For more corporate information please visit: This release has been reviewed and approved by Logan Anderson, CFO. St. James Gold further information, please contact: Tel: 1 (800) 278-2152 Email: [email protected] Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, 'forward-looking statements'). All other statements that are not historical facts, particularly statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance of the Company. Often, but not always, forward-looking statements can be identified through the use of words or phrases such as 'will likely result', 'are expected to', 'expects', 'will continue', 'is anticipated', 'anticipates', 'believes', 'estimated', 'intends', 'plans', 'forecast', 'projection', 'strategy', 'objective' and 'outlook'. Forward-looking statements contained in this news release are made based on reasonable estimates and assumptions made by management of the Company at the relevant time in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that are believed to be appropriate and reasonable in the circumstances. Forward-looking statements contained in this news release are made as of the date of this news release and the Company will not update any such forward-looking statements as a result of new information or if management's beliefs, estimates, assumptions or opinions change, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control, which could cause actual results, performance, achievements and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors outlined in the Company's Annual Information Form dated July 26, 2021 (the 'AIF') filed under the Company's profile on SEDAR at The Company cautions that the list of risk factors and uncertainties described in its AIF on SEDAR are not exhaustive and other factors could materially affect its results. New factors emerge from time to time, and it is not possible for the Company to consider all of them, or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.